Citation Report
List of articles citing

Parkinson disease subtypes

DOI: 10.1001/jamaneurol.2013.6233
JAMA Neurology, 2014, 71, 499-504.

Source: https://exaly.com/paper-pdf/59597547/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
364	What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?. **2014**, 23, 352-64		15
363	Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. *PLoS ONE*, **2014**, 9, e114566	3.7	16
362	A method for predicting the outcomes of combined pharmacologic and deep brain stimulation therapy for Parkinson's disease. *Lecture Notes in Computer Science*, **2014**, 17, 188-95	0.9	5
361	Genetic movement disorders in patients of Jewish ancestry. *JAMA Neurology*, **2014**, 71, 1567-72	17.2	21
360	The future of research in Parkinson disease. *JAMA Neurology*, **2014**, 71, 1351-2	17.2	24
359	Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. *JAMA Neurology*, **2014**, 71, 1290-5	17.2	72
358	Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. **2014**, 20, 640-3		27
357	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. **2014**, 261, 2112-8		28
356	Inverse Association of Parkinson Disease With Systemic Lupus Erythematosus: A Nationwide Population-based Study. **2015**, 94, e2097		20
355	Blood transcriptomics of drug-naïve sporadic Parkinson's disease patients. **2015**, 16, 876		51
354	Constitutional Study of Parkinson's Disease Patients Based on Traditional Chinese Medicine Pattern Differentiation. **2015**, 1, 170-175		2
353	Diagnosis of Parkinson’s disease: progress and future prospects. **2015**, 19		0
352	Effects of Auditory Rhythm and Music on Gait Disturbances in Parkinson's Disease. *Frontiers in Neurology*, **2015**, 6, 234	4.1	69
351	Aberrant Brain Network Efficiency in Parkinson's Disease Patients with Tremor: A Multi-Modality Study. **2015**, 7, 169		18
350	A Polysomnographic Study of Parkinson's Disease Sleep Architecture. *Parkinsons Disease*, **2015**, 2015, 570375	2.6	13
349	Heterogeneity of Monosymptomatic Resting Tremor in a Prospective Study: Clinical Features, Electrophysiological Test, and Dopamine Transporter Positron Emission Tomography. **2015**, 128, 1765-71		4
348	Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism. **2015**, 45, 59-69		5

347	Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. **2015**, 30, 359-67	121
346	Dopaminergic medication alters auditory distractor processing in Parkinson's disease. **2015**, 156, 45-56	19
345	DNA damage in neurodegenerative diseases. **2015**, 776, 84-97	111
344	Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls. **2015**, 36, 1105-9	24
343	Clinical spectrum of levodopa-induced complications. **2015**, 30, 80-9	153
342	Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement. **2015**, 21, 675-82	16
341	Parkinson's disease as a member of Prion-like disorders. **2015**, 207, 38-46	23
340	Dopamine transporter imaging in essential tremor with and without parkinsonian features. **2015**, 122, 1515-21	18
339	Postural instability in Parkinson Disease: to step or not to step. **2015**, 357, 146-51	6
338	Machine Learning Approach to Optimizing Combined Stimulation and Medication Therapies for Parkinson's Disease. **2015**, 8, 1025-32	42
337	Proteome-wide analysis of neural stem cell differentiation to facilitate transition to cell replacement therapies. **2015**, 12, 83-95	4
336	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. **2015**, 21, 629-34	118
335	Freezing of gait and affective theory of mind in Parkinson disease. **2015**, 21, 509-13	17
334	Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?. **2015**, 30, 632-7	14
333	Recognition and treatment of autonomic disturbances in Parkinson's disease. **2015**, 15, 1189-203	20
332	Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. **2015**, 589, 3702-13	65
331	Sensorimotor Integration in the Whisker System. **2015**,	5
330	Lack of Neuronal IFN-□IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia. **2015**, 163, 324-39	113

329	Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson's disease. **2015**, 262, 2433-9		11
328	Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes. **2015**, 122, 1115-24		30
327	Gait disorders. **2015**, 33, 249-68		36
326	Physical therapist interventions for Parkinson disease. **2015**, 95, 299-305		9
325	Speech disorders did not correlate with age at onset of Parkinson's disease. **2016**, 74, 117-21		9
324	Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinson's Disease*, **2016**, 2016, 9832839	2.6	110
323	Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. *PLoS ONE*, **2016**, 11, e0151841	3.7	94
322	Motor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson's Disease. *PLoS ONE*, **2016**, 11, e0152534	3.7	9
321	Structural Brain Alterations in Motor Subtypes of Parkinson's Disease: Evidence from Probabilistic Tractography and Shape Analysis. *PLoS ONE*, **2016**, 11, e0157743	3.7	19
320	Unusual motor and non-motor symptoms and signs in the early stage of Parkinson's disease. **2016**, 74, 781-784		10
319	Technology in Parkinson's disease: Challenges and opportunities. **2016**, 31, 1272-82		305
318	Motor subtype in Parkinson's disease: Different disorders or different stages of disease?. **2016**, 31, 957-61		56
317	Robust Bayesian hierarchical model using normal/independent distributions. **2016**, 58, 831-51		2
316	How Do I Examine for Re-Emergent Tremor?. *Movement Disorders Clinical Practice*, **2016**, 3, 216-217	2.2	16
315	Automatic Classification on Multi-Modal MRI Data for Diagnosis of the Postural Instability and Gait Difficulty Subtype of Parkinson's Disease. *Journal of Parkinson's Disease*, **2016**, 6, 545-56	5.3	7
314	Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. **2016**, 29, 727-734		42
313	Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. **2016**, 76, 759-77		66
312	Epidemiology of Parkinson Disease. **2016**, 34, 955-965		159

311	Is PIGD a legitimate motor subtype in Parkinson disease?. **2016**, 3, 473-7		32
310	Feature visualization and classification for the discrimination between individuals with Parkinson's disease under levodopa and DBS treatments. **2016**, 15, 169		11
309	Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review. **2016**, 62, 371-80		17
308	No relevant midbrain atrophy in Parkinson's disease. **2016**, 134, 378-381		4
307	Fractal measures of video-recorded trajectories can classify motor subtypes in Parkinson Disease. **2016**, 462, 12-20		4
306	Association between FGF20 rs12720208 gene polymorphism and Parkinson's disease: a meta-analysis. *Neurological Sciences*, **2016**, 37, 1119-26	3.5	3
305	Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson's disease patients. **2016**, 133, 330-7		34
304	The Association Between Parkinson's Disease Motor Impairments and Pain. **2016**, 17, 456-462		15
303	Parkinson Disease. **2016**, 85-115		9
302	Prevalence and factors associated with polyneuropathy in Parkinson disease. **2016**, 6, 89-94		2
301	New and emerging medical therapies in Parkinson's disease. **2016**, 17, 895-909		30
300	Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease. **2016**, 263, 888-894		24
299	Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage. **2016**, 312, 247-59		11
298	Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease. **2017**, 30, e3554		28
297	Pathology of Neurodegenerative Diseases. **2017**, 9,		360
296	Epidemiology of Parkinson's disease. **2017**, 124, 901-905		906
295	Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. **2017**, 13, 76-78		21
294	Structural and physiological neurovascular changes in idiopathic Parkinson's disease and its clinical phenotypes. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 3409-3421	7.3	30

293	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. **2017**, 32, 319-324		111
292	The cortical signature of symptom laterality in Parkinson's disease. **2017**, 14, 433-440		33
291	Diagnosis and Management of Parkinson's Disease. **2017**, 37, 118-126		61
290	Motor Complications of Dopaminergic Medications in Parkinson's Disease. **2017**, 37, 147-157		30
289	Counseling At-Risk Parkinson Disease Cohorts: Integrating Emerging Evidence. **2017**, 5, 100-107		7
288	Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?. **2017**, 17, 34		64
287	Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters. *Scientific Reports* , **2017**, 7, 44872	4.9	20
286	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. **2017**, 6, 4		14
285	Cardiac parasympathetic dysfunction in the early phase of Parkinson's disease. **2017**, 264, 333-340		17
284	Subtypes evaluation of motor dysfunction in Parkinson's disease using neuromelanin-sensitive magnetic resonance imaging. **2017**, 638, 145-150		15
283	Association of UV radiation with Parkinson disease incidence: A nationwide French ecologic study. **2017**, 154, 50-56		15
282	Dystonia and ataxia progression in spinocerebellar ataxias. **2017**, 45, 75-80		27
281	Disrupted Brain Network Hubs in Subtype-Specific Parkinson's Disease. **2017**, 78, 200-209		20
280	Vocal tremor: where are we at?. **2017**, 25, 475-479		6
279	Mechanistic evaluation of neuroprotective effect of estradiol on rotenone and 6-OHDA induced Parkinson's disease. **2017**, 69, 1178-1185		6
278	Weight in Parkinson's Disease: Phenotypical Significance. **2017**, 134, 891-919		13
277	Synucleinopathies: common features and hippocampal manifestations. **2017**, 74, 1485-1501		26
276	Default-mode network connectivity in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease. **2017**, 264, 152-160		23

275	The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. **2017**, 16, 615-622		25
274	Alterations of the circadian system in Parkinson's disease patients. **2017**, 32, 682-692		35
273	Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases. **2017**, 18,		48
272	Altered Functional Connectivity Density in Subtypes of Parkinson's Disease. **2017**, 11, 458		16
271	Changes in the symptom frequency of rapid eye movement sleep behavior disorder according to disease duration. **2017**, 1,		2
270	Progress toward an integrated understanding of Parkinson's disease. **2017**, 6, 1121		17
269	Parkinson's disease tremors and serotonin. **2018**, 141, 624-626		9
268	Intercepting Parkinson disease non-motor subtypes: A proof-of-principle study in a clinical setting. **2018**, 388, 186-191		6
267	Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson's Disease. *Journal of Parkinsons Disease*, **2018**, 8, 333-340	5.3	3
266	Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. **2018**, 187, 134-140		39
265	Rehabilitation of Parkinson□s Disease. **2018**, 161-170		3
264	Is Parkinson's Disease a Neurodevelopmental Disorder and Will Brain Organoids Help Us to Understand It?. **2018**, 27, 968-975		26
263	Differences in cognitive performance in nondemented Parkinson's disease: A latent profile analysis of cognitive subtypes. **2018**, 40, 777-789		4
262	The genetics of Parkinson disease. **2018**, 42, 72-85		254
261	The relation between plasma □synuclein level and clinical symptoms or signs of Parkinson's disease. **2018**, 52, 243-251		22
260	Alpha-synucleinopathies. **2017**, 145, 339-353		28
259	Comparison of two motor subtype classifications in de novo Parkinson's disease. **2018**, 54, 74-78		20
258	MPTP-induced parkinsonism: an historical case series. **2018**, 17, 300-301		18

257	Imaging Parkinsonian Pathology in Substantia Nigra with MRI. **2018**, 6, 1		11
256	Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. **2018**, 275, 5-13		22
255	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. **2018**, 10,		305
254	The future of pharmacogenetics in Parkinson's disease treatment. **2018**, 19, 171-174		2
253	Patterns of grey matter loss associated with motor subscores in early Parkinson's disease. **2018**, 17, 498-504		24
252	Neuromodulatory procedures for gait disorders in Parkinson's disease. **2018**, 118, 13-19		4
251	Dysfunction of mitochondria as the basis of Parkinson's disease. **2018**, 6, 174-181		1
250	Identifying of factor associated with parkinson's disease subtypes using random forest. **2018**, 1108, 012064		4
249	Wearable sensors for Parkinson's disease: which data are worth collecting for training symptom detection models. **2018**, 1, 64		72
248	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. **2018**, 5, 1460-1477		142
247	Circadian Rhythm Abnormalities in Parkinson's Disease from Humans to Flies and Back. **2018**, 19,		23
246	Resting-state network connectivity in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease. **2018**, 395, 147-152		10
245	PET Molecular Imaging in Familial Parkinson's Disease. **2018**, 142, 177-223		4
244	The presence of depression in de novo Parkinson's disease reflects poor motor compensation. *PLoS ONE*, **2018**, 13, e0203303	3.7	19
243	The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?. **2018**, 9, 2047		23
242	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. **2018**, 41, 63-87		78
241	Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease. **2018**, 53, 70-75		7
240	Impaired topographic organization in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease. **2018**, 56, 52-57		17

239	The role of substantia nigra sonography in the differentiation of Parkinson's disease and multiple system atrophy. **2018**, 7, 15		6
238	Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease. *Frontiers in Neurology*, **2018**, 9, 560	4.1	22
237	Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease. *Frontiers in Neurology*, **2018**, 9, 234	4.1	17
236	Cognitive Profiles and Hub Vulnerability in Parkinson's Disease. *Frontiers in Neurology*, **2018**, 9, 482	4.1	23
235	Motor Subtypes of Parkinson's Disease Can Be Identified by Frequency Component of Postural Stability. **2018**, 18,		9
234	Analysis of the clinical features of early Parkinson's disease with comparatively integrated intestinal function. *Neurological Sciences*, **2018**, 39, 1847-1856	3.5	4
233	Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. **2018**, 115, E8567-E8576		34
232	Treatment options for postural instability and gait difficulties in Parkinson's disease. **2019**, 19, 1229-1251		12
231	Factors Associated With Postoperative Confusion and Prolonged Hospital Stay Following Deep Brain Stimulation Surgery for Parkinson Disease. **2020**, 86, 524-529		3
230	Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts. **2019**, 14, 969-982		3
229	Olfactory Identification among Various Subtypes of Parkinson Disease. **2019**, 81, 167-173		7
228	Postural Instability in Parkinson's Disease: A Review. **2019**, 9,		24
227	Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study. *Scientific Reports*, **2019**, 9, 797	4.9	36
226	Botulinum toxin for the treatment of tremor. **2019**, 63, 31-41		20
225	Chronotherapies for Parkinson's disease. **2019**, 174, 16-27		21
224	New insights into the role of microRNAs and long noncoding RNAs in most common neurodegenerative diseases. **2019**, 120, 8908-8918		25
223	Drug treatment strategies for depression in Parkinson disease. **2019**, 20, 1351-1363		33
222	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. **2019**, 126, 933-995		15

221	The influence of initial symptoms on phenotypes in spinocerebellar ataxia type 3. **2019**, 7, e00719		5
220	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. **2019**, 65, 39-48		23
219	Different Dopaminergic Dysfunctions Underlying Parkinsonian Akinesia and Tremor. **2019**, 13, 550		8
218	Comparing postural instability and gait disorder and akinetic-rigid subtyping of Parkinson disease and their stability over time. **2019**, 26, 1212-1218		10
217	Evaluation of tremor interference with control of voluntary reaching movements in patients with Parkinson's disease. **2019**, 16, 38		3
216	AAV2/DJ-mediated alpha-synuclein overexpression in the rat substantia nigra as early stage model of Parkinson's disease. **2019**, 378, 1-14		1
215	Tandem gait abnormality in Parkinson disease: Prevalence and implication as a predictor of fall risk. **2019**, 63, 83-87		6
214	Long non-coding SNHG1 in cancer. **2019**, 494, 38-47		52
213	Gait impairments in Parkinson's disease. **2019**, 18, 697-708		146
212	Tremor-Dominant in Parkinson Disease: The Relevance to Iron Metabolism and Inflammation. **2019**, 13, 255		11
211	Peroxisomal dysfunction in neurodegenerative diseases. **2019**, 42, 393-406		25
210	Current and Potential Approaches for Defining Disease Signatures: a Systematic Review. **2019**, 67, 550-558		2
209	Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice. **2019**, 20,		8
208	Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All. **2019**, 36, 103-113		21
207	Zonisamide Administration Improves Fatty Acid □Oxidation in Parkinson's Disease. **2018**, 8,		4
206	Outcomes in Lesion Surgery versus Deep Brain Stimulation in Patients with Tremor: A□Systematic Review and Meta-Analysis. *World Neurosurgery*, **2019**, 123, 443-452.e8	2.1	5
205	Pathogenesis-targeted therapeutic strategies in Parkinson's disease. **2019**, 34, 41-44		25
204	Postural control after unexpected external perturbation: Effects of Parkinson's disease subtype. **2019**, 64, 12-18		7

203	Altered Local Field Potential Relationship Between the Parafascicular Thalamic Nucleus and Dorsal Striatum in Hemiparkinsonian Rats. **2019**, 35, 315-324		8
202	Genetics of REM Sleep Behavior Disorder. **2019**, 589-609		1
201	Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease. **2019**, 30, 1352-1368		8
200	Technology-Based Objective Measures Detect Subclinical Axial Signs in Untreated, de novo Parkinson's Disease. *Journal of Parkinson's Disease*, **2020**, 10, 113-122	5.3	10
199	Axes of a revolution: challenges and promises of big data in healthcare. **2020**, 26, 29-38		97
198	Differentiating Parkinson Disease Subtypes Using Clinical Balance Measures. **2020**, 44, 34-41		4
197	Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease. **2020**, 25, 102103		33
196	Study on the Clinical Features of Parkinson's Disease With Probable Rapid Eye Movement Sleep Behavior Disorder. *Frontiers in Neurology*, **2020**, 11, 979	4.1	1
195	Characterization of idiopathic Parkinson's disease subgroups using quantitative gait analysis and corresponding subregional striatal uptake visualized using F-FP-CIT positron emission tomography. *Gait and Posture*, **2020**, 82, 167-173	2.6	
194	Arylsulfatase A (ASA) in Parkinson's Disease: From Pathogenesis to Biomarker Potential. **2020**, 10,		3
193	Independently together: subthalamic theta and beta opposite roles in predicting Parkinson's tremor. **2020**, 2, fcaa074		9
192	Different iron deposition patterns in Parkinson's disease subtypes: a quantitative susceptibility mapping study. **2020**, 10, 2168-2176		2
191	Index. **2020**, 160-162		
190	Validity and sensitivity of instrumented postural and gait assessment using low-cost devices in Parkinson's disease. **2020**, 17, 149		4
189	Unsupervised clustering of dopamine transporter PET imaging discovers heterogeneity of parkinsonism. **2020**, 41, 4744-4752		4
188	Association of MAPT subhaplotypes with clinical and demographic features in Parkinson's disease. **2020**, 7, 1557-1563		2
187	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. **2020**, 78, 56-60		4
186	Perceptual Characterization of Voice Quality in Nonadvanced Stages of Parkinson's Disease. **2020**,		2

185	The P2X7 Receptor: Central Hub of Brain Diseases. **2020**, 13, 124		32
184	Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. *Frontiers in Neurology*, **2020**, 11, 731	4.1	6
183	The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson's disease. **2020**, 20, 292		5
182	Multi-Dimensional, Short-Timescale Quantification of Parkinson's Disease and Essential Tremor Motor Dysfunction. *Frontiers in Neurology*, **2020**, 11, 886	4.1	2
181	Association of NOTCH2NLC Repeat Expansions With Parkinson Disease. *JAMA Neurology*, **2020**, 77, 1559-1563	17.1	25
180	Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases. **2020**, 52, 1486-1495		20
179	Comparison of Three Motor Subtype Classifications in Parkinson's Disease Patients. *Frontiers in Neurology*, **2020**, 11, 601225	4.1	9
178	Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson's disease. **2020**, 56,		7
177	Association between positive history of essential tremor and disease progression in patients with Parkinson's disease. *Scientific Reports*, **2020**, 10, 21749	4.9	3
176	Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes: A Comprehensive Review. **2020**, 12, 109-129		6
175	Postural instability in Parkinson's disease: Review and bottom-up rehabilitative approaches. **2020**, 50, 479-487		8
174	Association Analyses of Autonomic Dysfunction and Sympathetic Skin Response in Motor Subtypes of Parkinson's Disease. *Frontiers in Neurology*, **2020**, 11, 577128	4.1	4
173	Use of Functional Magnetic Resonance Imaging to Assess How Motor Phenotypes of Parkinson's Disease Respond to Deep Brain Stimulation. **2020**, 23, 515-524		8
172	Striatal shape alteration as a staging biomarker for Parkinson's Disease. **2020**, 27, 102272		2
171	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. *Frontiers in Neurology*, **2020**, 11, 450	4.1	15
170	Identifying and predicting Parkinson's disease subtypes through trajectory clustering via bipartite networks. *PLoS ONE*, **2020**, 15, e0233296	3.7	6
169	The role of disease duration and severity on novel clinical subtypes of Parkinson disease. **2020**, 73, 31-34		6
168	The Hypothesis That Refuses to Die. **2020**, 95-104		

167 Preface 1 The Question. **2020**, ix-x

166 The Shaky Six and the Second Reality. **2020**, 1-10

165 Pieces of a Puzzle?. **2020**, 11-24

164 Disease Redefinition: A Tough Pill to Swallow. **2020**, 25-32

163 Disease Subtypes: The Promise and the Fallacy. **2020**, 33-40

162 Protein Paradox. **2020**, 41-56

161 The Fault in Our Models. **2020**, 57-70

160 Biomarkers: The Promise and the Fallacy. **2020**, 71-80

159 Lessons from Oncology. **2020**, 81-86

158 Symptomatic vs. Disease-Modifying Therapies. **2020**, 87-94

157 Our Living Dissonance. **2020**, 105-110

156 The Scientific and Lay Narratives. **2020**, 111-124

155 Challenges Viewed from Afar. **2020**, 125-132

154 The Moonshot: Population-Based Studies of Aging. **2020**, 133-138

153 Predictions for the 2020s and Beyond. **2020**, 139-147

152 Note Added at Press Time Reviving LOF. **2020**, 150-150

151 References. **2020**, 151-159

150 Epilogue. **2020**, 148-149

149	Parkinson's disease: etiopathogenesis and treatment. **2020**, 91, 795-808		120
148	Speech disorder and vocal tremor in postural instability/gait difficulty and tremor dominant subtypes of Parkinson's disease. **2020**, 127, 1295-1304		9
147	Longitudinal Monitoring of Parkinson's Disease in Different Ethnic Cohorts: The DodoNA and LONG-PD Study. *Frontiers in Neurology*, **2020**, 11, 548	4.1	5
146	Diagnosis and Treatment of Parkinson Disease: A Review. **2020**, 323, 548-560		490
145	Obstructive Sleep Apnea in Neurodegenerative Disorders: Current Evidence in Support of Benefit from Sleep Apnea Treatment. **2020**, 9,		20
144	Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review. *Journal of Parkinsons Disease*, **2020**, 10, 31-45	5.3	22
143	Electrophysiological resting state networks of predominantly akinetic-rigid Parkinson patients: Effects of dopamine therapy. **2020**, 25, 102147		3
142	Saliva in Health and Disease. **2020**,		2
141	Neuropsychiatric feature profiles of patients with Lewy body dementia. **2020**, 194, 105832		13
140	Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychotics. **2021**, 75, 9-17		1
139	Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review. *Movement Disorders Clinical Practice*, **2021**, 8, 175-192	2.2	5
138	Robust Bayesian Analysis of Early-Stage Parkinson's Disease Progression Using DaTscan Images. **2021**, 40, 549-561		2
137	Clinical and laboratory measures of balance and comparison of balance performances according to postural instability and gait disorders in individuals with Parkinson's disease. **2021**, 38, 34-40		2
136	Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders. **2021**, 249-295.e17		
135	Detection of postural control in early Parkinson's disease: Clinical testing vs. modulation of center of pressure. *PLoS ONE*, **2021**, 16, e0245353	3.7	5
134	Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. **2021**, 7, e557		4
133	Medical treatment of the motor features of Parkinson disease. **2021**, 164-203.e14		1
132	Parkinson's Disease: Is there a Role for Dietary and Herbal Supplements?. **2021**, 20, 343-365		1

131	Seeing Parkinson Disease in the Retina. **2021**, 139, 189-190		1
130	Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. **2021**, 11,		3
129	Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing. *Npj Parkinsons Disease*, **2021**, 7, 28	9.7	4
128	Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. **2021**, 84, 105-111		3
127	Variable Effects of PD-Risk Associated SNPs and Variants in Parkinsonism-Associated Genes on Disease Phenotype in a Community-Based Cohort. *Frontiers in Neurology*, **2021**, 12, 662278	4.1	0
126	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. *Journal of Parkinsons Disease*, **2021**, 11, 757-765	5.3	1
125	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease. **2021**, 12, 2311		10
124	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. **2021**, 152, 105295		2
123	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease. **2021**, 268, 4203-4212		1
122	FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. **2021**, 12, 675725		2
121	Machine Learning Prediction of Parkinson Disease Onset and Subtype Using Germline Variants.		
120	The inconsistency and instability of Parkinson's disease motor subtypes. **2021**, 88, 13-18		1
119	Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view. **2021**, 88, 51-57		5
118	Parkinson's Disease Genetics and Pathophysiology. **2021**, 44, 87-108		19
117	Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study. **2021**, 36, 2569-2582		5
116	Tremor Syndromes: An Updated Review. *Frontiers in Neurology*, **2021**, 12, 684835	4.1	12
115	Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson's disease. **2021**, 1		0
114	Family history of hand tremor in patients with early Parkinson's disease. **2021**, 90, 161-164		

113	Remote smartphone monitoring of Parkinson's disease and individual response to therapy. **2021**,		11
112	Intrasubject relationship between striatal 18F-FP-CIT uptake and cardiac 123I-MIBG uptake differs by motor subtype in early Parkinson disease. **2021**, 100, e26995		0
111	A Cross-Sectional Comprehensive Assessment of the Profile and Burden of Non-motor Symptoms in Relation to Motor Phenotype in the Nigeria Parkinson Disease Registry Cohort. *Movement Disorders Clinical Practice*, **2021**, 8, 1206-1215	2.2	0
110	New insights into pathogenesis of l-DOPA-induced dyskinesia. **2021**, 86, 104-113		1
109	Comprehensive subtyping of Parkinson's disease patients with similarity fusion: a case study with BioFIND data. *Npj Parkinson's Disease*, **2021**, 7, 83	9.7	1
108	Could New Generations of Sensors Reshape the Management of Parkinson's Disease?. **2021**, 5, 18		0
107	Parkinsonism and tremor syndromes. **2021**, 120018		1
106	Dual-task clinical and functional MRI correlates in Parkinson's disease with postural instability and gait disorders. **2021**, 91, 88-95		0
105	Neurodegenerative Motor Conditions. **2022**, 106-114		
104	Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson's disease motor subtypes: a prospective pilot study with 3-month follow-up. **2021**, 16, 1336-1343		1
103	Artificial intelligence applied to neuroimaging data in Parkinsonian syndromes: Actuality and expectations. **2021**, 18, 1753-1773		1
102	Parkinsonism. **2021**, 82-120.e21		
101	Multimodal phenotypic axes of Parkinson's disease. *Npj Parkinson's Disease*, **2021**, 7, 6	9.7	5
100	Impact of Monoaminergic Neuromodulators on the Development of Sensorimotor Circuits. **2015**, 243-273		5
99	The Natural History of Parkinson's Disease. **2017**, 129-137		1
98	Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them. **2020**,		2
97	The Relationship Between Speech Characteristics and Motor Subtypes of Parkinson's Disease. **2020** , 29, 2145-2154		2
96	Rapid motor fluctuations reveal short-timescale neurophysiological biomarkers of Parkinson's disease. **2020**, 17, 046042		3

95	Multi-layer Trajectory Clustering: a Network Algorithm for Disease Subtyping.. **2020**, 6,		1
94	Leveraging selective hippocampal vulnerability among Alzheimer disease subtypes reveals a novel tau binding partner SERPINA5.		2
93	Association between peripheral inflammation and DATSCAN data of the striatal nuclei in different motor subtypes of Parkinson Disease.		1
92	Treating the Motor Symptoms of Parkinson Disease. **2016**, 22, 1064-85		7
91	Recent advances in understanding and treatment of Parkinson's disease. **2020**, 9, 6		8
90	KSNR Clinical Consensus Statements: Rehabilitation of Patients with Parkinson's Disease. **2020**, 13,		1
89	Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease. *PLoS ONE*, **2014**, 9, e107585	3.7	11
88	Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients. *PLoS ONE*, **2015**, 10, e0135287	3.7	16
87	Cerebrospinal Fluid Amyloid 1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. **2016**, 9, 89-96		15
86	Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. **2019**, 12, 113-119		10
85	Fluoxetine-mediated inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of Parkinson's disease. **2018**, 10, 4188-4196		6
84	Role of microtubule-associated protein 6 glycosylated with Gal-(1,3)-GalNAc in Parkinson's disease. **2019**, 11, 4597-4610		5
83	[Diagnostic value of tremor analysis in identifying the early Parkinson's syndrome]. **2019**, 51, 1096-1102		1
82	Protective Effects of the Caffeine Against Neurodegenerative Diseases. **2019**, 26, 5137-5151		12
81	Defining Speech Subtypes in De Novo Parkinson Disease: Response to Long-term Levodopa Therapy. **2021**, 97, e2124-e2135		8
80	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. **2022**, 202, 108822		3
79	Beneficial effects of L-arginine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuronal degeneration in substantia nigra of Balb/c mice. **2016**, 5, 140		0
78	Botulinum Toxin Treatment in Parkinson Disease and Atypical Parkinsonian Disorders. **2018**, 23-48		2

77	Effects of Korean Medicine on Postural Instability and Gait Difficulty in Patient with Parkinsonism: Retrospective Study. **2017**, 38, 96-102		5
76	Association between Parkinson's Disease subtypes and tests of physical function: the 360-degree turn test is most predictive.		
75	Plasma catecholamine levels in the early stages of treatment-naïve Parkinson's disease. **2018**, 46, 792-801		
74	Indications for Deep Brain Stimulation Therapy in Parkinson's Disease. **2019**, 3-19		
73	Nanobiotechnology in Parkinson's Disease. **2019**, 177-208		
72	Post-Operative Electrode Placement Prediction in Deep Brain Stimulation Using Support Vector Regression. **2019**,		1
71	Robust Feature Engineering for Parkinson Disease Diagnosis: New Machine Learning Techniques (Preprint).		
70	The different syndromes in Parkinson's disease: an overview. **2020**, 235-249		
69	Salivary Biomarkers in Neurologic Diseases. **2020**, 121-152		
68	Genome-Wide Association Study Meta-Analysis for Parkinson's Disease Motor Subtypes.		
67	Preface 2 Enter Patient. **2020**, xi-xii		
66	Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity.		
65	for Disorders in Parkinson's. **2021**, 137-159		
64	Efficacy of C-Mill gait training for improving walking adaptability in early and middle stages of Parkinson's disease. *Gait and Posture*, **2021**, 91, 79-85	2.6	1
63	Multi-view Clustering with mvReliefF for Parkinson's Disease Patients Subgroup Detection. *Lecture Notes in Computer Science*, **2020**, 287-298	0.9	
62	Deep Brain Stimulation for Parkinson's Disease. **2020**, 171-191		
61	Environmental and genetic risk factors for Parkinson's disease. **2020**, 57-71		
60	Progression of symptoms in Parkinson's disease. **2020**, 3-20		0

59	Multimodal phenotypic axes of Parkinson's disease.		
58	Rapid Motor Fluctuations Reveal Short-Timescale Neurophysiological Biomarkers of Parkinson's Disease.		
57	Robust Feature Engineering for Parkinson Disease Diagnosis: New Machine Learning Techniques. *JMIR Biomedical Engineering*, **2020**, 5, e13611	1.3	2
56	Effects of L-arginine pre-treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's diseases in Balb/c mice. *Iranian Journal of Neurology*, **2015**, 14, 195-203	0.6	2
55	Risk Factors for Tremor in a Population of Patients with Severe Mental Illness: An 18-year Prospective Study in a Geographically Representative Sample (The Curacao Extrapyramidal Syndromes Study XI). *Tremor and Other Hyperkinetic Movements*, **2017**, 7, 468	2	
54	TOWARD AN OBJECTIVE METHOD TO CLASSIFY TREMOR DOMINANT AND POSTURAL INSTABILITY AND GAIT DIFFICULTY SUBTYPES OF PARKINSON'S DISEASE: A PILOT STUDY. *Biomedical Sciences Instrumentation*, **2017**, 53, 138-142	0.7	2
53	The Role of TMEM230 Gene in Parkinson's Disease. *Journal of Parkinsons Disease*, **2018**, 8, 469-477	5.3	4
52	24-hour ambulatory blood pressure alterations in patients with Parkinson's disease. *Brain and Behavior*, **2021**, e2428	3.4	2
51	Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. *Journal of Parkinsons Disease*, **2021**,	5.3	0
50	Effect of onset age on the levodopa threshold dosage for dyskinesia in Parkinson's disease. *Neurological Sciences*, **2021**, 1	3.5	0
49	Evaluating a Speech-Specific and a Computerized Step-Training-Specific Rhythmic Intervention in Parkinson's Disease: A Cross-Over, Multi-Arms Parallel Study. *Frontiers in Rehabilitation Sciences*, **2022**, 2,		0
48	Resting State Functional Connectivity Signatures of MRgFUS Vim Thalamotomy in Parkinson's Disease: A Preliminary Study.. *Frontiers in Neurology*, **2021**, 12, 786734	4.1	1
47	Plasma Metabolite Signature Classifies Male LRRK2 Parkinson's Disease Patients.. *Metabolites*, **2022**, 12,	5.6	0
46	Cortico-cortical connectivity is normalised by levodopa in tremor-dominant Parkinson's disease.		
45	Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson's disease.. *Scientific Reports*, **2022**, 12, 5483	4.9	0
44	Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?. *PLoS ONE*, **2021**, 16, e0261302	3.7	0
43	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. *Scientific Reports*, **2021**, 11, 23645	4.9	2
42	NRM 2021 Abstract Booklet.. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 11-309	7.3	

41	Constructing Prediction Models for Freezing of Gait by Nomogram and Machine Learning: A Longitudinal Study.. *Frontiers in Neurology*, **2021**, 12, 684044	4.1	0
40	Proof of Concept in Artificial-Intelligence-Based Wearable Gait Monitoring for Parkinson's Disease Management Optimization.. *Biosensors*, **2022**, 12,	5.9	0
39	Data_Sheet_1.docx. **2020**,		
38	Presentation_1.PDF. **2018**,		
37	Table_1.DOCX. **2018**,		
36	Data_Sheet_1.PDF. **2020**,		
35	Image_1.tiff. **2020**,		
34	Image_2.tiff. **2020**,		
33	Image_3.tiff. **2020**,		
32	Table_1.pdf. **2020**,		
31	Table_1.DOCX. **2019**,		
30	Hierarchical Denoising of Ordinal Time Series of Clinical Scores.. *IEEE Journal of Biomedical and Health Informatics*, **2022**, PP,	7.2	1
29	Evaluating Oculomotor Tests before and after Vestibular Rehabilitation in Patients with Parkinson's Disease: A Pilot Pre-Post Study.. *Parkinsons Disease*, **2022**, 2022, 6913691	2.6	
28	Differential Effects of Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation on Motor Subtypes in Parkinson's Disease.. *World Neurosurgery*, **2022**,	2.1	0
27	Characterization of Parkinson's Disease Subtypes and Related Attributes. *Frontiers in Neurology*, **2022**, 13,	4.1	
26	Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson disease. *Npj Parkinsons Disease*, **2022**, 8,	9.7	2
25	Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders. *Journal of Nuclear Medicine*, **2022**, 63, 27S-32S	8.9	2
24	Gray and white matter alterations in different predominant side and type of motor symptom in Parkinson's disease. *CNS Neuroscience and Therapeutics*,	6.8	1

23	Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson in an international setting. *BMJ Open*, **2022**, 12, e049530	3	
22	The impact of cognitive impairment of individuals with Parkinson disease on their caregivers mental health: A systematic review protocol. *PLoS ONE*, **2022**, 17, e0271480	3.7	1
21	Age Cut Off for Early Onset Parkinson Disease: Recommendations from the EOPD Disease Task Force. *Movement Disorders Clinical Practice*,	2.2	1
20	Genetics of validated Parkinson disease subtypes in the Oxford Discovery and Tracking Parkinson cohorts. jnnp-2021-327376		0
19	Artificial Intelligence-Based Clustering and Characterization of Parkinson Disease Trajectories.		
18	Editorial: Biomarkers from multi-tracer and multi-modal neuroimaging in age-related neurodegenerative diseases. 14,		
17	Tremor in Parkinson Disease: From Pathophysiology to Advanced Therapies. **2022**, 12,		2
16	Magnetic Resonance guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.		0
15	Investigation of Factors Affecting Spontaneous Eye Blink Frequency in Parkinson's Disease.		0
14	Genetically-informed prediction of short-term Parkinson disease progression. **2022**, 8,		0
13	Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI study. **2022**, 105, 32-38		0
12	Association of Depression With Early Occurrence of Postural Instability in Parkinson Disease.		0
11	Cerebellar alterations in Parkinson disease with postural instability and gait disorders.		0
10	Bilateral globus pallidus interna deep brain stimulation in Parkinson disease: Therapeutic effects and motor outcomes prediction in a short-term follow up. 16,		0
9	**2023**, 464-474		0
8	Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes. **2023**, 109, 105318		0
7	Early-onset Parkinson's disease: An assessment of unmet psychosocial needs. **2023**, 110, 105395		0
6	The effect of standing posture on amplitude and variability of postural tremor in Parkinson disease. **2023**, 805, 137220		0

5	Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations. **2023**, 24, 3739	1
4	Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories. **2023**, 13,	0
3	How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson disease?. **2023**, 23, 107-122	0
2	Smaller Cerebellar Lobule VIIb is Associated with Tremor Severity in Parkinson Disease.	0
1	Speech and gait abnormalities in motor subtypes of de-novo Parkinson's disease.	0